DK2510012T3 - Antistoffer mod c4.4a og anvendelser deraf - Google Patents

Antistoffer mod c4.4a og anvendelser deraf Download PDF

Info

Publication number
DK2510012T3
DK2510012T3 DK10798996.4T DK10798996T DK2510012T3 DK 2510012 T3 DK2510012 T3 DK 2510012T3 DK 10798996 T DK10798996 T DK 10798996T DK 2510012 T3 DK2510012 T3 DK 2510012T3
Authority
DK
Denmark
Prior art keywords
ser
gly
leu
ala
val
Prior art date
Application number
DK10798996.4T
Other languages
English (en)
Inventor
Beatrix Stelte-Ludwig
Ricarda Finnern
Anke Mayer-Bartschmid
Simone Greven
Jan Tebbe
Lars Linden
Yong-Jiang Cao
Gabriele Leder
Axel Harrenga
Frank Dittmer
Juergen Franz
Jörg Willuda
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK2510012T3 publication Critical patent/DK2510012T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Isoleret antistof eller antigenbindende fragment deraf, der binder specifikt til aminosyrerne 1-85 af SEQ ID NO: 1, hvor antistoffet eller det antigenbindende fragment deraf internaliseres efter binding til C4.4a-udtrykkende celler, og hvor antistoffet eller det antigenbindende fragment deraf omfatter de variable CDR-sekvenser af tung kæde: H-CDR1, der omfatter SEQ ID NO: 45, H-CDR2, der omfatter SEQ ID NO: 46, og H-CDR3, der omfatter SEQ ID NO: 47, og hvor antistoffet eller det antigenbindende fragment deraf omfatter de variable CDR-sekvenser af let kæde: L-CDR1, der omfatter SEQ ID NO: 48, L-CDR2, der omfatter SEQ ID NO: 49, og L-CDR3, der omfatter SEQ ID NO: 50.
2. Antistof eller antigenbindende fragment ifølge krav 1, der omfatter en variabel sekvens af tung kæde som vist ved SEQ ID NO: 33 og en variabel sekvens af let kæde som vist ved SEQ ID NO: 29, eller en variabel sekvens af tung kæde som vist ved SEQ ID NO: 51 og en variabel sekvens af let kæde som vist ved SEQ ID NO: 52.
3. Antistof ifølge krav 1 eller 2, som er et IgG-antistof.
4. Antigenbindende fragment ifølge krav 1 eller 2, som er et scFv-, Fab-, Fab'-fragment eller et F (ab')2_fragment.
5. Antistof eller antigenbindende fragment ifølge et hvilket som helst af ovennævnte krav, som er et monoklonalt antistof eller et antigenbindende fragment.
6. Antistof eller antigenbindende fragment ifølge et hvilket som helst af ovennævnte krav, som er et humant, humaniseret eller kimært antistof eller et antigenbindende fragment.
7. Antistof-lægemiddel-konjugat, der omfatter et antistof eller et antigenbindende fragment deraf ifølge kravene 1 til 6.
8. Isoleret nukleinsyresekvens, der koder for antistoffet eller det antigenbindende fragment ifølge kravene 1 til 6.
9. Vektor, der omfatter en nukleinsyresekvens ifølge krav 8.
10. Isoleret celle, der udtrykket et antistof eller et antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 6 og/eller omfatter en nukleinsyre ifølge krav 8 eller en vektor ifølge krav 9.
11. Isoleret celle ifølge krav 10, hvor cellen er en prokaryot eller en eukaryot celle.
12. Fremgangsmåde til fremstilling af et antistof eller et antigenbindende fragment ifølge et hvilket som helst af kravene 1 til 6, der omfatter dyrkning af en celle ifølge krav 11 og oprensing af antistoffet eller det antigenbindende fragment.
13. Antistof eller antigenbindende fragment ifølge kravene 1 til 6 eller et antistof-lægemiddel-konjugat ifølge krav 7 til anvendelse som et medikament.
14. Antistof eller antigenbindende fragment ifølge kravene 1 til 6 til anvendelse som et diagnostisk middel.
15. Antistof eller antigenbindende fragment ifølge kravene 1 til 6 eller et antistof-lægemiddel-konjugat ifølge krav 7 til anvendelse som et medikament til behandling af cancer.
16. Farmaceutisk sammensætning, der omfatter et antistof eller et antigenbindende fragment ifølge kravene 1 til 6 eller et antistof-lægemiddel-konjugat ifølge krav 7.
17. Kombination af en farmaceutisk sammensætning ifølge krav 16 og en eller flere terapeutisk aktive forbindelser.
DK10798996.4T 2009-12-09 2010-12-08 Antistoffer mod c4.4a og anvendelser deraf DK2510012T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26
PCT/EP2010/069216 WO2011070088A1 (en) 2009-12-09 2010-12-08 Anti-c4.4a antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK2510012T3 true DK2510012T3 (da) 2017-07-31

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10798996.4T DK2510012T3 (da) 2009-12-09 2010-12-08 Antistoffer mod c4.4a og anvendelser deraf

Country Status (28)

Country Link
US (2) US20120321619A1 (da)
EP (2) EP2510012B1 (da)
JP (3) JP5989544B2 (da)
KR (1) KR101931820B1 (da)
CN (1) CN102812047B (da)
AR (1) AR079340A1 (da)
AU (1) AU2010329904B2 (da)
BR (1) BR112012013915A8 (da)
CA (1) CA2783338A1 (da)
CY (1) CY1119051T1 (da)
DK (1) DK2510012T3 (da)
ES (1) ES2632748T3 (da)
HK (1) HK1178920A1 (da)
HR (1) HRP20170973T1 (da)
HU (1) HUE034847T2 (da)
IL (1) IL219801A (da)
IN (1) IN2012DN05175A (da)
LT (1) LT2510012T (da)
MX (1) MX2012006593A (da)
NZ (1) NZ600470A (da)
PL (1) PL2510012T3 (da)
PT (1) PT2510012T (da)
RS (1) RS56161B1 (da)
RU (1) RU2577977C2 (da)
SI (1) SI2510012T1 (da)
TW (1) TWI488642B (da)
WO (1) WO2011070088A1 (da)
ZA (1) ZA201203498B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5881604B2 (ja) * 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
KR102023496B1 (ko) * 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
AU2015315332A1 (en) 2014-09-09 2017-03-30 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
CA2982536C (en) 2015-04-17 2023-04-18 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
AU2016365423A1 (en) * 2015-12-04 2018-07-12 The Regents Of The University Of California Novel antibodies for the treatment of cancers
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
CN110325210A (zh) 2017-01-11 2019-10-11 小利兰·斯坦福大学托管委员会 Rspo替代物分子
CA3050133A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
US20210309711A1 (en) * 2018-07-20 2021-10-07 Duke University Anti-lypd3 car t-cell therapy for the treatment of cancer
WO2020096006A1 (ja) * 2018-11-08 2020-05-14 国立大学法人香川大学 希少糖含有組成物の製造方法および希少糖含有組成物
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
EP3986461A4 (en) * 2019-06-21 2023-07-05 Children's National Medical Center METHOD AND COMPOSITION FOR A BINDING MOLECULE TARGETED AGAINST CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN THE HLA-A1 0201 CONTEXT
WO2023175117A1 (en) 2022-03-16 2023-09-21 Glycotope Gmbh Antibodies against lypd3
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
ATE214075T1 (de) * 1996-05-31 2002-03-15 Health Research Inc Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001023553A2 (en) * 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
AU2005249490B2 (en) * 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
ES2636451T3 (es) * 2006-12-08 2017-10-05 Monopar Therapeutics Inc. Epítopo del receptor del activador del plasminógeno tipo uroquinasa
KR102023496B1 (ko) * 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도

Also Published As

Publication number Publication date
ES2632748T3 (es) 2017-09-15
US20170158775A1 (en) 2017-06-08
EP2510012A1 (en) 2012-10-17
LT2510012T (lt) 2017-07-25
BR112012013915A8 (pt) 2017-12-26
HUE034847T2 (en) 2018-03-28
HRP20170973T1 (hr) 2017-09-22
BR112012013915A2 (pt) 2017-01-10
KR20120116958A (ko) 2012-10-23
SI2510012T1 (sl) 2017-08-31
JP2013513369A (ja) 2013-04-22
CN102812047B (zh) 2015-08-26
ZA201203498B (en) 2015-10-28
TW201134485A (en) 2011-10-16
JP2018019721A (ja) 2018-02-08
US20120321619A1 (en) 2012-12-20
AR079340A1 (es) 2012-01-18
IL219801A0 (en) 2012-07-31
CA2783338A1 (en) 2011-06-16
EP3144323A2 (en) 2017-03-22
JP5989544B2 (ja) 2016-09-07
KR101931820B1 (ko) 2018-12-21
IL219801A (en) 2016-08-31
IN2012DN05175A (da) 2015-10-23
EP2510012B1 (en) 2017-04-19
NZ600470A (en) 2015-02-27
TWI488642B (zh) 2015-06-21
JP2016104820A (ja) 2016-06-09
HK1178920A1 (en) 2013-09-19
CY1119051T1 (el) 2018-01-10
EP3144323A3 (en) 2017-05-31
RU2577977C2 (ru) 2016-03-20
AU2010329904B2 (en) 2015-07-09
MX2012006593A (es) 2012-06-28
JP6240696B2 (ja) 2017-11-29
PL2510012T3 (pl) 2017-09-29
WO2011070088A1 (en) 2011-06-16
AU2010329904A1 (en) 2012-06-14
RS56161B1 (sr) 2017-11-30
RU2012128343A (ru) 2014-01-20
PT2510012T (pt) 2017-07-13
CN102812047A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
DK2510012T3 (da) Antistoffer mod c4.4a og anvendelser deraf
US11866495B2 (en) Anti-CEACAM6 antibodies and uses thereof
US20140322220A1 (en) Anti-FGFR2 Antibodies and Uses Thereof
US20160237160A1 (en) Anti-tweakr antibodies and uses thereof
WO2015189143A1 (en) Aglycosyl anti-tweakr antibodies and uses thereof
NZ624534B2 (en) Anti-fgfr2 antibodies and uses thereof